Press coverage about Mednax (NYSE:MD) has been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mednax earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the company an impact score of 56 out of 100, indicating that recent media coverage is somewhat likely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Look for Shares of Mednax Inc to Potentially Rebound after Yesterday’s 14.66% Sell Off (mysmartrend.com)
- MEDNAX, INC. (NYSE:MD) Files An 8-K Results of Operations and Financial Condition (4-traders.com)
- MEDNAX (MD) Q2 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Mednax, Inc (NYSE:MD) Rating Lowered to Sell at BidaskClub (americanbankingnews.com)
- MEDNAX Reports Second Quarter GAAP EPS of $0.69 (finance.yahoo.com)
A number of analysts have weighed in on MD shares. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Thursday, April 13th. Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a report on Thursday, May 4th. Jefferies Group LLC reissued a “hold” rating and set a $53.00 price objective (up previously from $50.00) on shares of Mednax in a report on Thursday, July 6th. BidaskClub raised shares of Mednax from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 13th. Finally, ValuEngine cut shares of Mednax from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the company’s stock. Mednax currently has a consensus rating of “Hold” and a consensus price target of $65.89.
Shares of Mednax (NYSE:MD) traded down 15.51% during midday trading on Friday, hitting $47.73. 3,638,964 shares of the company’s stock traded hands. The company has a 50 day moving average of $57.87 and a 200 day moving average of $63.24. Mednax has a 52 week low of $46.70 and a 52 week high of $72.13. The stock has a market cap of $4.43 billion, a P/E ratio of 15.20 and a beta of 0.44.
Mednax (NYSE:MD) last released its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 12.81% and a net margin of 9.54%. The company had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. During the same quarter in the prior year, the business posted $1.03 earnings per share. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. On average, equities analysts forecast that Mednax will post $3.58 EPS for the current fiscal year.
In other news, Director Md Pascal J. Goldschmidt sold 1,969 shares of the stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the completion of the transaction, the director now owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Joseph M. Calabro sold 23,327 shares of the stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the completion of the transaction, the insider now directly owns 296,379 shares of the company’s stock, valued at approximately $16,300,845. The disclosure for this sale can be found here. In the last three months, insiders sold 33,074 shares of company stock valued at $1,830,508. Company insiders own 2.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/07/30/mednax-nysemd-getting-somewhat-positive-press-coverage-report-finds-updated-updated-updated.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.